Item 1(a). | Name of Issuer: |
Vaxcyte, Inc. (the “Issuer”)
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
353 Hatch Drive
Foster City, California
Item 2(a). | Name of Person Filing: |
This joint statement on Schedule 13G is being filed by Longitude Venture Partners II, L.P. (“LVPII”), Longitude Capital Partners II, LLC (“LCPII” and together with LVPII, the “Reporting Entities”) and Juliet Tammenoms Bakker (“Tammenoms Bakker”) and Patrick G. Enright (“Enright” and together with Tammenoms Bakker, the “Managing Members”). The Reporting Entities and the Managing Members collectively are referred to as the “Reporting Persons”.
Item 2(b) | Address of Principal Business Office, or if None, Residence: |
The address of the principal business office of each Reporting Person is 2740 Sand Hill Road, Second Floor, Menlo Park, California 94025.
LCPII is a limited liability company organized under the laws of the State of Delaware. LVPII is a limited partnership organized under the laws of the State of Delaware. Each of the Managing Members is a citizen of the United States of America.
Item 2(d). | Title of Class of Securities: |
Common Stock, $0.001 par value per share (“Common Stock”).
92243G108
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
| (a) | Amount beneficially owned: |
See Row 9 of the cover page for each Reporting Person. LVPII is the record owner of the 3,106,350 shares of Common Stock (the “LVPII Shares”). As the general partner of LVPII, LCPII may be deemed to beneficially own the LVPII Shares. As the managing members of LCPII, each of the Managing Members also may be deemed to beneficially own the LVPII Shares.
See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.*